Goldman Sachs
DYN icon

Goldman Sachs’s Dyne Therapeutics DYN Stock Holding History

Goldman Sachs’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$31.2M Sell
1,723,116
-560,075
-25% -$9.66M ﹤0.01% 2017
2025
Q4 		$44.7M Buy
2,283,191
+382,976
+20% +$7.25M 0.01% 1600
2025
Q3 		$24M Buy
1,900,215
+559,772
+42% +$6.38M ﹤0.01% 2083
2025
Q2 		$12.8M Buy
1,340,443
+345,557
+35% +$3.8M ﹤0.01% 2544
2025
Q1 		$10.4M Buy
994,886
+366,183
+58% +$5.24M ﹤0.01% 2657
2024
Q4 		$14.8M Sell
628,703
-41,781
-6% -$1.24M ﹤0.01% 2417
2024
Q3 		$24.1M Sell
670,484
-1,425,265
-68% -$56.7M ﹤0.01% 1899
2024
Q2 		$74M Buy
2,095,749
+434,661
+26% +$12.6M 0.01% 938
2024
Q1 		$47.2M Buy
1,661,088
+500,316
+43% +$11.3M 0.01% 1205
2023
Q4 		$15.4M Sell
1,160,772
-347,370
-23% -$3.39M ﹤0.01% 2151
2023
Q3 		$13.5M Sell
1,508,142
-501,387
-25% -$5.4M ﹤0.01% 2137
2023
Q2 		$22.6M Buy
2,009,529
+515,079
+34% +$6.08M ﹤0.01% 1742
2023
Q1 		$17.2M Buy
1,494,450
+658,433
+79% +$8.55M ﹤0.01% 1954
2022
Q4 		$9.69M Buy
836,017
+438,447
+110% +$5.07M ﹤0.01% 2612
2022
Q3 		$5.05M Buy
397,570
+331,527
+502% +$3.8M ﹤0.01% 3129
2022
Q2 		$454K Sell
66,043
-12,514
-16% -$86.2K ﹤0.01% 5142
2022
Q1 		$757K Sell
78,557
-6,061
-7% -$51.6K ﹤0.01% 5049
2021
Q4 		$1.01M Buy
84,618
+45,349
+115% +$637K ﹤0.01% 4832
2021
Q3 		$637K Sell
39,269
-142,877
-78% -$2.53M ﹤0.01% 5049
2021
Q2 		$3.83M Buy
182,146
+79,633
+78% +$1.5M ﹤0.01% 3588
2021
Q1 		$1.59M Buy
102,513
+57,794
+129% +$1.12M ﹤0.01% 4215
2020
Q4 		$939K Sell
44,719
-133,268
-75% -$2.64M ﹤0.01% 4236
2020
Q3 		$3.59M Buy
+177,987
New +$3.91M ﹤0.01% 3141

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Goldman Sachs's DYN Position: Q1 2026 in Review

Goldman Sachs reduced its Dyne Therapeutics (DYN) stake by 25% in Q1 2026, selling an estimated $9.66M and leaving 1,723,116 shares worth $31.2M. The position accounts for ﹤0.01% of the portfolio, ranked #2017.

Goldman Sachs first reported a position in DYN in Q3 2020 and has held it in 23 quarters since. The position peaked at $74M in Q2 2024. 227 funds tracked by Wall St. Rank hold DYN as of Q1 2026.

  • Goldman Sachs held 1,723,116 shares of Dyne Therapeutics worth $31.2M as of Q1 2026.
  • Goldman Sachs sold 560,075 Dyne Therapeutics shares in Q1 2026, an estimated $9.66M.
  • Dyne Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #2017 holding.
  • Goldman Sachs first reported a position in Dyne Therapeutics in Q3 2020 and has held it in 23 quarters since.
  • Goldman Sachs's Dyne Therapeutics position peaked at $74M in Q2 2024.
  • 227 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.